The Effect of Lisdexamfetamine Dimesylate Augmentation Therapy in Adult Patients with Residual Symptoms of Major Depressive Disorder, with or without Adult ADHD
Objective: Evaluate the Efficacy of Lisdexamfetamine Dimesylate (LDX) Augmentation for Treatment of MDD in
Patients with or without Comorbid Attention Deficit Hyperactivity Disorder (ADHD).
WHO reports that there are 322 million people suffering from depression worldwide. The symptoms of depression are
associated with impairment of psycho socio occupational functioning. 60% of Major Depressive Disorder (MDD) patients do
not achieve adequate response or remission with SSRI monotherapy. American Psychiatric Association (APA) recommends
augmentation therapy with various medications such as mood stabilizers, antipsychotic medication, stimulants,
anticonvulsants, etc. Atypical antipsychotics are beneficial, but adverse events such as metabolic effects are a concern. Studies
have shown the efficacy of stimulants in treating patients with partial or poor responders who were treated with monotherapy
Conclusion: Non-responders and partial responders of MDD patients with or without ADHD show considerable improvement
in their psychosocial occupational functioning when LDX was added as an augmenter.
Index Terms- Augmentation therapy, Cognition, Lisdexamfetamine Dimesylate, Major Depressive Disorder.